B3GNT5

Across TCGA pan-cancer cohorts, B3GNT5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated B3GNT5 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher B3GNT5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated B3GNT5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, UCEC, and LGG are the cancer types where B3GNT5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	36	view →
UCEC	DFS	Median	II,III,IV	0.941	0.430	.008	26	view →
LGG	OS	Median	All	0.103	0.890	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SARC	DFS	Median	All	0.024	0.591	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

B3GNT5–BLCA (OS)

Open the BLCA breakdown →